Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the CD8+ immune infiltrate using [89Zr]Zr-Df-IAB22M2C-PET

Trial details

Who runs it

Universitaetsklinikum Tuebingen AöR

Trial code

EU 2024-512219-37-00

Record updated

2026. szeptember 22.

Original description

Feasibility of the early detection of immune-mediated ICT side effects by semiquantitative assessment of CD8+ lymphocyte infiltration using noninvasive [89Zr]Zr-Df-IAB22M2C PET imaging.Read full original descriptionShow less

Feasibility of the early detection of immune-mediated ICT side effects by semiquantitative assessment of CD8+ lymphocyte infiltration using noninvasive [89Zr]Zr-Df-IAB22M2C PET imaging.

Inclusion: Male or female patients ≥18 years of age at the time of signing the informed consent; Patients with metastasized or irresectable melanoma; Eastern Cooperative Oncology Group Performance (ECOG) Status ≤2; Patients scheduled for ICT as recommended by the interdisciplinary tumor board; Understand and voluntarily sign an informed consent document prior to any study related assessments/ procedures; Able to adhere to the study visit schedule and other protocol requirements; Consent to practice double-barrier contraception until end of the study (28 days after last [89Zr]Zr-Df-IAB22M2C injection): Females of childbearing potential (FCBP1) and male patients with female partner of childbearing potential1 are willing to use highly effective contraceptive methods at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 28 days after end of study treatment after the last dose. Recommendations (CTFG Recommendations related to contraception and pregnancy testing in clinical trials. Version 1.1, 2020) for highly effective contraceptive methods are: a) combined hormonal contraception associated with inhibition of ovulation • oral • intravaginal • transdermal b) progestogen-only hormonal contraception associated with inhibition of ovulation • oral • injectable • implantable c) intrauterine device (IUD) d) intrauterine hormone - releasing system (IUS) e) bilateral tubal occlusion f) vasectomized partner (2) g) sexual abstinence (3) 1For the purpose of this document, a female is considered of childbearing potential (FCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. For the purpose of this document, a man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy. 2Vasectomised partner is a highly effective birth control method provided that partner is the sole sexual partner of the WOCBP trial participant and that the vasectomised partner has received medical assessment of the surgical success. 3In the context of the CTFG guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.

Exclusion: Major surgery within 4 weeks of starting study treatment. Patients must have recovered from any effects of major surgery; Patients receiving any systemic chemotherapy or radiotherapy within 2 weeks prior to study treatment or a longer period depending on the defined characteristics of the agents used; Known hypersensitivity to [89Zr]Zr-Df-IAB22M2C or its components or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product; Persistent toxicity (>Grade 2) according to Common Terminology Criteria for Adverse Events [CTCAE] version 5.0, caused by previous cancer therapy, excluding alopecia; Clinical signs of active infection (>Grade 2 according to CTCAE version 5.0); Heart failure NYHA III/IV; Participation in other therapeutic clinical trials or observation period of competing trials; Patients not able to declare meaningful informed consent on their own; Women during pregnancy and lactation; female patients of childbearing potential or male patients with female partners of childbearing potential not willing to practice effective contraception by using a double-barrier method from Day 1 until 28 days postdose; Male patients planning to donate sperm while participating in the study and for at least 28 days after end of study treatment.

EU CTIS 2024-512219-37-00